ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

Rhea-AI Summary

ProMIS Neurosciences Inc. (OTCQB: ARFXF) has completed a US$7M private placement of convertible unsecured debentures, aimed at supporting their drug development efforts for neurodegenerative diseases. The debentures, convertible at US$0.10 per share, will mature on March 22, 2026, with a 1% annual interest. Major investors include figures like Mike Gordon and organizations such as the Kraft Group. ProMIS plans to accelerate the clinical testing of its PMN310 antibody and expand its partnerships and product portfolio, while preparing for the transition of its CEO by the end of 2021.

Positive

• Completed US$7M private placement of convertible debentures to support drug development.
• Plans to advance PMN310 antibody into clinical testing, enhancing prospects for Alzheimer's treatment.
• Secured investment from reputable figures and organizations, increasing credibility and financial backing.
• Investors granted rights to participate in future equity offerings, indicating strong confidence in company growth.

Negative

• CEO Dr. Elliot Goldstein announced retirement, creating potential leadership uncertainty during transition period.

TORONTO and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the "Debentures").

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimer’s Fund, and Jeremy Sclar of WS Development Group. “After conducting diligence with a number of experts in the field, we are impressed with the tremendous potential of ProMIS Neurosciences and its unique platform of drug candidates to have a profound impact in the fight against Alzheimer's and other neurodegenerative diseases.  Our group is pleased to provide funding for the next phase of the company's exciting future”, stated Mike Gordon of Fenway Sports Group.

“We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas,” said Gene Williams, ProMIS Executive Chairman.

Debenture Terms

The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company’s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or “VWAP” of the common shares).

The Debenture mature on March 22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion price upon raising US$50M in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof at its election. Amounts redeemed in common shares on the Maturity Date will be subject to TSX acceptance.

The investors were granted a right to participate, on a pro rata basis, in subsequent company offerings of equity securities for cash consideration pursuant to a public offering or a private placement.

The Debentures and any common shares issued on conversion are subject to a four-month hold period that expires on July 22, 2021. Net proceeds will be used for working capital and general corporate purposes.

ProMIS plans to accelerate progress toward a number of top priorities, including:

• Advancing the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
• Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data;
• Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform;
• Advancing our partnered diagnostic programs;
• Achieving NASDAQ listing;
• Expanding our Board of Directors; and
• Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.
  

Retirement of our CEO

Finally, a note of great appreciation for our CEO, Dr. Elliot Goldstein. Elliot, who just turned 70, has announced his intention to retire from a full time role by the end of 2021. Even though Elliot is irreplaceable, ProMIS has initiated a search for a new CEO to help us achieve our potential. “Elliot has been a close friend and valued business partner for decades,” said Gene Williams, “without his significant contributions, we would not have been able to take ProMIS from just a great science idea to a company with a growing portfolio of therapies that have the potential to be life-altering for patients. On behalf of the entire ProMIS community, and patients who in the future may benefit from our therapies, I offer Elliot our sincere thanks and gratitude”.

“ProMIS Neurosciences was launched six years ago based on a world class scientific platform from our CSO and scientific founder, Dr. Neil Cashman. Playing a key role in this endeavor has been one of the most challenging yet rewarding experiences of my 40 odd years in pharmaceutical drug development. I am delighted for this exciting new phase of the Company”, stated Dr. Elliot Goldstein, ProMIS CEO.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn.

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

FAQ

What is the purpose of the US$7M funding announced by ProMIS Neurosciences on March 22, 2021?

The funding is aimed at supporting the development of antibody therapeutics for neurodegenerative diseases, specifically advancing the PMN310 Alzheimer's treatment into clinical trials.

What are the terms of the convertible debentures issued by ProMIS Neurosciences?

The debentures are convertible at US$0.10 per share, have a 1% annual interest rate, and mature on March 22, 2026.

Who are the notable investors in ProMIS Neurosciences' recent funding round?

Investors include Mike Gordon of Fenway Sports Group, the Kraft Group, and Henry McCance, co-founder of the Cure Alzheimer’s Fund.

What are ProMIS Neurosciences' plans for the funding received?

The funds will be used for working capital, advancing drug candidates, enhancing partnerships, and achieving NASDAQ listing.

What impact does the CEO's retirement have on ProMIS Neurosciences?

The retirement of CEO Dr. Elliot Goldstein by the end of 2021 may lead to leadership changes and potential transitional challenges as the company seeks a replacement.